Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081583 · ClinicalTrials.gov registry record · Early Phase 1
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
A Early Phase 1 study, sponsored by Washington State University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
NCT05081583 is a Early Phase 1 study that has completed, run by Washington State University. The registered enrollment target is 22 participants.
The verdict
NCT05081583, a Early Phase 1 study, has completed, sponsored by Washington State University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade. Goldenseal products are marketed as licensed natural health products in Canada and as dietary supplements in the United States. Natural products made from dried roots of the goldenseal plant are purported to have therapeutic value and are used to self-treat a range of medical complications, including the common cold, allergic rhinitis, and digestive disorders, such as diarrhea and constipation. Based on a previous clinical study, goldenseal have been shown to precipitate pharmacokinetic interactions with metformin in healthy volunteers. This follow-up study aims to evaluate the goldenseal-metformin interaction in type 2 diabetic patients. Results from this proposed clinical study will (1) characterize the pharmacokinetic interaction between the botanical dietary supplement goldenseal and anti-diabetic drug metformin, (2) provide evidence-based recommendations to mitigate drug interaction risks, and (3) contribute to the development of a comprehensive strategy for effectively assessing other potential natural-product drug interactions.
Interventions
- DRUG Midazolam Hcl 1Mg/Ml Inj
- DIETARY_SUPPLEMENT Goldenseal (Hydrastis canadensis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2023-08-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05081583
The ClinicalTrials.gov registry entry for NCT05081583 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington State University, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam Hcl 1Mg/Ml Inj is the first listed.
NCT05081583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05081583 about?
NCT05081583 is a clinical study titled "Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients". Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade. Goldenseal products are marketed as licensed natural health products in Canada and as dietary supplements in the United ...
What is the current status of trial NCT05081583?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2021-09-16. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT05081583?
The interventions under investigation include: Midazolam Hcl 1Mg/Ml Inj (DRUG), Goldenseal (Hydrastis canadensis) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05081583?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.